TY - JOUR
T1 - Harmonizing clinical sequencing and interpretation for the Emerge III Network
AU - eMERGE Consortium
AU - Abrams, Debbie
AU - Adunyah, Samuel
AU - Afshar, Majid
AU - Albers, David
AU - Albertson-Junkans, Ladia
AU - Albrecht, Jen
AU - Ames, Darren
AU - Antommaria, Armand
AU - Appelbaum, Paul
AU - Aragam, Krishna
AU - Aronson, Sandy
AU - Aufox, Sharon
AU - Babb, Larry
AU - Balasubramanian, Adithya
AU - Banta, Shawn
AU - Basford, Melissa
AU - Bathon, Joan
AU - Bauer, Christopher
AU - Baxter, Samantha
AU - Behr, Meckenzie
AU - Benoit, Barbara
AU - Bhat, Ashwini
AU - Bhoj, Elizabeth
AU - Bielinski, Sue
AU - Bland, Sarah
AU - Blasi, Paula
AU - Blout, Carrie
AU - Boerwinkle, Eric
AU - Bolesta, Scott
AU - Borthwick, Kenneth
AU - Bottinger, Erwin
AU - Bowen, Deb
AU - Bowser, Mark
AU - Brand, Harrison
AU - Breitkopf, Carmen Radecki
AU - Brilliant, Murray
AU - Brodeur, Wendy
AU - Bruce, Kevin
AU - Castillo, Lisa
AU - Chisholm, Rex
AU - Gordon, Adam
AU - Hoell, Christin
AU - Kho, Abel
AU - Roy-Puckelwartz, Megan
AU - Starren, Justin
AU - Walunas, Theresa
AU - Wehbe, Firas
AU - Wicklund, Cathy
AU - Rasmussen-Torvik, Laura J.
AU - Smith, Maureen E.
N1 - Publisher Copyright:
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Background: The eMERGE III Network was tasked with harmonizing genetic testing protocols linking multiple sites and investigators. Methods: DNA capture panels targeting 109 genes and 1551 variants were constructed by two clinical sequencing centers for analysis of 25,000 participant DNA samples collected at 11 sites where samples were linked to patients with electronic health records. Each step from sample collection, data generation, interpretation, reporting, delivery and storage, were developed and validated in CAP/CLIA settings and harmonized across sequencing centers. Results: A compliant and secure network was built and enabled ongoing review and reconciliation of clinical interpretations while maintaining communication and data sharing between investigators. Mechanisms for sustained propagation and growth of the network were established. An interim data freeze representing 15,574 sequenced subjects, informed the assay performance for a range of variant types, the rate of return of results for different phenotypes and the frequency of secondary findings. Practical obstacles for implementation and scaling of clinical and research findings were identified and addressed. The eMERGE protocols and tools established are now available for widespread dissemination. Conclusions: This study established processes for different sequencing sites to harmonize the technical and interpretive aspects of sequencing tests, a critical achievement towards global standardization of genomic testing. The network established experience in the return of results and the rate of secondary findings across diverse biobank populations. Furthermore, the eMERGE network has accomplished integration of structured genomic results into multiple electronic health record systems, setting the stage for clinical decision support to enable genomic medicine.
AB - Background: The eMERGE III Network was tasked with harmonizing genetic testing protocols linking multiple sites and investigators. Methods: DNA capture panels targeting 109 genes and 1551 variants were constructed by two clinical sequencing centers for analysis of 25,000 participant DNA samples collected at 11 sites where samples were linked to patients with electronic health records. Each step from sample collection, data generation, interpretation, reporting, delivery and storage, were developed and validated in CAP/CLIA settings and harmonized across sequencing centers. Results: A compliant and secure network was built and enabled ongoing review and reconciliation of clinical interpretations while maintaining communication and data sharing between investigators. Mechanisms for sustained propagation and growth of the network were established. An interim data freeze representing 15,574 sequenced subjects, informed the assay performance for a range of variant types, the rate of return of results for different phenotypes and the frequency of secondary findings. Practical obstacles for implementation and scaling of clinical and research findings were identified and addressed. The eMERGE protocols and tools established are now available for widespread dissemination. Conclusions: This study established processes for different sequencing sites to harmonize the technical and interpretive aspects of sequencing tests, a critical achievement towards global standardization of genomic testing. The network established experience in the return of results and the rate of secondary findings across diverse biobank populations. Furthermore, the eMERGE network has accomplished integration of structured genomic results into multiple electronic health record systems, setting the stage for clinical decision support to enable genomic medicine.
KW - Clinical sequencing
KW - Electronic health record
KW - EMERGE
KW - Harmonization
KW - Next generation sequencing
UR - http://www.scopus.com/inward/record.url?scp=85095626801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095626801&partnerID=8YFLogxK
U2 - 10.1101/457523
DO - 10.1101/457523
M3 - Article
AN - SCOPUS:85095626801
JO - Free Radical Biology and Medicine
JF - Free Radical Biology and Medicine
SN - 0891-5849
ER -